So, SSYS, sitting at about $130 gets a paltry 9% upgrade to $140, and the entire sector goes ape-sheet?
For an overbought stock in an overbought market, this is a rather pedestrian and paltry upgrade, IMHO.
But, irrational exuberance knows no bounds. LOL.
It's interesting that SSYS gets a 9% upgrade ($130 to $140) and this segment goes wild?
A 8% premium for a segment which is already overbought in a market which is already overbought is NOT much at all. What's the big deal with $140 for SSYS? I don't get it. I'd rather take my chances with ONVO.
Danger, Will Robinson!
Actually there is danger in both directions, as evidenced by the option market for VJET.
That's really not much of an upgrade. Less than 10% from here.
Irrational exuberance 10-fold in this segment right now.
There is no good entry point on either side, put or call.
Buy or sell the stock instead.
Options for this puppy are useless.
I've traded in and out of all three.
ONVO is purely speculative at this point, but may offer the highest total return if everything pans out for them.
You can't really go wrong long-term with DDD, VJET, or SSYS.
Absolutely nothing wrong with taking profits. I took mine at 11.35 this morning.
Institutions and big money are drawing a line in the sand. IF there is a pullback, I doubt that it will be much below $10/share, if even that far. Good news (of any kind) will cause a spike higher even from these levels.
Congrats to all, whether you've taken profits or are still in the game. Go ONVO!
Nov 14, 2013 (MarketLine via COMTEX) -- Keryx Biopharmaceuticals, Inc., a
biopharmaceutical company developing renal therapeutics, has reported that net
loss for the third quarter ended September 30, 2013 was $15.65 million, or $0.19
loss per share, compared to a net loss of $5.47 million, or $0.08 loss per
share, for the same quarter ended September 30, 2012.
Operating loss for the third quarter ended September 30, 2013 was $15.73
million, compared to an operating loss of $5.53 million for the same quarter
ended September 30, 2012.
Net loss for the nine months ended September 30, 2013 was $29.06 million, or
$0.36 loss per share, compared to a net loss of $16.09 million, or $0.22 loss
per share, for the same period ended September 30, 2012.
Operating loss for the nine months ended September 30, 2013 was $29.34 million,
compared to an operating loss of $20.40 million for the same period ended
September 30, 2012.
ONVO is definitely a gamble, but if you believe in their value proposition (reduced animal testing by big pharma, reduced costs to big pharma for testing, quicker time to market for drugs, et al) then the reward may very well be worth the risk.
This disruptive technology uses 3D printing in a bio-space (even more disruptive). There are no true competitors at the moment. I could easily see them doing $50M business in a year and $300M in five years.
Big pharma is VERY interested in them.